Immunotoxicity of the anticancer drug CI-994 in rats: Effects on lymphoid tissue

Archives of Toxicology

Volumn 73, Issue 3, 1999, Pages 168-174

  Graziano, Michael J ^a   Galati, Anthony J ^a   Walsh, Kathleen M ^a  

^a PFIZER INC   (United States)

Author keywords

Acetyldinaline; CI 994; Immunotoxicity; Lymphocyte proliferation; Rats

Indexed keywords

4 N ACETYLDINALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MALE; MONOCYTE; NEUTROPHIL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT; THYMUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BONE MARROW; CELL DIVISION; CONCANAVALIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKOCYTES; LYMPHOID TISSUE; MALE; ORGAN SIZE; PHENYLENEDIAMINES; RATS; RATS, WISTAR; SPLEEN; THYMUS GLAND; TIME FACTORS;

ANIMALIA;

EID: 0033041942     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002040050602     Document Type: Article

References (28)

1. Animal Welfare Act (1966) Code of Federal Regulations (CFR), Title 9 (Animals and Animal Products), Subchapter A (Animal Welfare), Parts 1, 2, and 3; as amended in 1970, 1976, and 1985.
2. Berger MR, Richter H, Seelig MH, Eibl H, Schmähl D (1990) New cytostatics - more activity and less toxicity. Cancer Treat Rev 17: 143-154
3. Braun DP, Harris JE (1981) Modulation of the immune response by chemotherapy. Pharmacol Ther 14: 89-122
4. Department of Health and Human Services (1985) Guide for the care and use of laboratory animals. NIH Publication no. 86-23 National Institutes of Health, Bethesda, Maryland
5. El-Betagi HM, Martens ACM, Lelieveld P, Haroun EA, Hagenbeek A (1993) Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells - preclinical studies in a relevant rat model for human acute myelocytic leukemia. Leukemia 7: 1795-1800
6. Everett NB, Caffrey RW, Rieke WO (1964) Recirculation of lymphocytes. Ann New York Acad Sci 113: 887-897
7. Grant LD, Kaesberg PR, Ershler WB (1991) Immunologic effects of cancer chemotherapy. In: Powis G, Hacker MP (eds) The toxicity of anticancer drugs. Pergamon Press, Elmsford, New York, pp 167-197
8. Graziano MJ, Pilcher GD, Walsh KM, Kasali OB, Radulovic L (1997) Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs. Invest New Drugs 15: 295-310
9. Howard CT, Roberts BJ, Vincent PW, Elliot WL (1992) N-acetyldinaline. A small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 33: 393
10. Ioannidou E, Lialiaris T, Mourelatos D, Dozi-Vassiliades J (1989) Synergistic induction of cytogenetic damage by alkylating an tineoplastics and 5-azacytidine in human lymphocytes. Environ Mol Mutagen 14: 6-12
11. Kempf RA, Mitchell MS (1984) Effects of chemotherapeutic agents on the immune system. I. Cancer Invest 2: 459-466
12. Kempf RA, Mitchell MS (1985) Effects of chemotherapeutic agents on the immune system. II. Cancer Invest 3: 23-33
13. Kraker AJ, Wolven A, Fry DW, Klohs WD (1991) cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl)benzamide (PD 123654, GOE 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 32: 396
14. Lebrec H, Blot C, Pequet S, Roger R, Bobuon C, Pallardy M (1994) Immunotoxicological investigation using pharmaceutical drugs: in vivo evaluation of immune effects. Toxicol Appl Pharmacol 23: 159-168
15. LoRusso PM, Dernchik L, Foster B, Knight J, Bissery M-C, Polin LM, Leopold WR, Corbett TH (1996) Preclinical antitumor activity of CI-994. Invest New Drugs 14: 349-356
16. LoRusso PM, Wozniak A, Foster B, Zalupski M, Shields A, McCormick J, Meyer M, Radulovic L, Corbett T (1997) Phase I clinical trial of CI-994. Proc Am Soc Clin Oncol 16: 213a
17. Luster MI, Dean JH, Moore JA (1982) Evaluation of immune functions in toxicology. In: Hayes AW (ed) Principles and methods of toxicology. Raven Press, New York, pp 561-586
18. Luster MI, Munson AE, Thomas PT, Holsapple MP, Fenters JD, White KL Jr., Lauer LD, Germolec DR, Rosenthal GJ, Dean JH (1988) Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam Appl Toxicol 10: 2-19
19. Luster MI, Portier C, Pait DG, White KL Jr., Gennings C, Munson AE, Rosenthal GJ (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam Appl Toxicol 18: 200-210
20. Robinson SH, Brecher G, Lourie IS, Haley JE (1965) Leukocyte labeling in rats during and after continuous infusion of tritiated thymidine: implications for lymphocyte longevity and DNA reutilization. Blood 26: 281-295
21. Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD (1995) Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int J Cancer 62: 636-642
22. Schauenstein K, Rossi K, Csordas A (1988) Differential inhibition of mitogen induced T cell proliferation by 5-azacytidine and cytosine-arabinoside. Biochem Biophys Res Commun 151: 548-553
23. Schuurman H-K, Kuper CF, Vos JG (1994) Histopathology of the immune system as a tool to assess immunotoxicity. Toxicology 86: 187-212
24. Sharma BS (1993) Effects of cyclophosphamide on in vitro human lymphocyte culture and mitogenic stimulation. Transplantation 35: 165-168
25. Sprent J, Tough DF (1994) Lymphocyte life-span and memory. Science 265: 1395-1400
26. Verdier F (1992) Specific methods to evaluate the immune system. Functional assays. J Toxicol Clin Exp 12: 405-419
27. Vos JG, van Loveran H (1987) Immunotoxicity testing in the rat. Adv Mod Environ Toxicol 13: 167-180
28. Winkelstein A (1984) Immune suppression resulting from various cytotoxic agents. Clinics Immunol Allergy 4: 295-315